ArticleBMC ophthalmology2026
Relationship between serum IgG4 levels and clinical activity of ophthalmopathy in Graves' disease.
Article in BMC ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe aim of this study was to evaluate the association between serum IgG4 levels and the presence, activity, and severity of thyroid eye disease (TED) within a single cohort of patients with Graves' disease, and to assess the potential role of IgG4 as a complementary biomarker across the clinical spectrum of the disease.
methodsThis cross-sectional study included 46 patients diagnosed with Graves' disease, comprising 23 patients with TED and 23 without TED. All participants underwent a comprehensive ophthalmological and biochemical evaluation, including thyroid function testing, autoantibody profiling, and measurement of serum total IgG, IgG4, and the IgG4/IgG ratio. Disease activity was assessed using the Clinical Activity Score (CAS ≥ 3), and disease severity was classified according to the European Group on Graves' Orbitopathy (EUGOGO) criteria.
resultsSerum IgG4 levels were significantly higher in TED patients than in those without TED (97.7 ± 92.6 vs. 52.9 ± 42.9 mg/dL; p = 0.041). The IgG4/IgG ratio was also increased (8.05 ± 6.75% vs. 4.44 ± 3.42%; p = 0.027). Moderate-to-severe TED showed higher IgG4 and IgG4/IgG values than mild disease (p = 0.042 and p = 0.041). Active TED had greater IgG4 levels than inactive cases (132.0 ± 112.1 vs. 60.2 ± 45.4 mg/dL; p = 0.049). IgG4 correlated positively with activity and severity. The proportion of patients with IgG4 ≥ 135 mg/dL was 8.7% in patients without TED and 21.7% in those with TED, with higher proportions particularly observed in active and moderate-to-severe cases.
conclusionElevated serum IgG4 levels in TED were associated with the presence, activity, and severity of the disease. These findings suggest that serum IgG4 may reflect underlying immunological activity across the TED spectrum. Measurement of serum IgG4 may serve as a complementary biomarker to conventional clinical scoring systems in the assessment of disease activity and severity. To clarify the clinical significance and temporal dynamics of these associations, large-scale prospective and longitudinal studies incorporating imaging and tissue-based evaluations are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.